---
source_pdf: "https://drive.google.com/file/d/1pQU__W2WEzI2-PI0Jw0LoqY75L9XlIyH/view"
drive_folder: "Portfolio/Ryght"
type: portfolio
company: Ryght
ingested: 2025-12-27
original_filename: "Ryght Investor Deck 19JULY2024.pdf"
---

> **Original:** [View Original PDF](https://drive.google.com/file/d/1pQU__W2WEzI2-PI0Jw0LoqY75L9XlIyH/view)

## Slide 1: Investor Presentation

# RIGHT.
Investor Presentation
June 2024

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 2: Vision

# RIGHT.
Vision

To accelerate drug development
through an AI-driven, real-time
global network of patients, sites,
and sponsors to simplify trials,
speed time to market and save
lives

© 2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute
or reproduce.

## Slide 3: The Problem

# RIGHT.
The Problem
The increasing volume and complexity of clinical trials is crippling existing antiquated systems

### 66,000 recruiting studies and growing

**Chart: Number of Registered Studies Over Time and Some Significant Events (as of 2024-05-10)**

| Year | Number of Registered Studies |
|---|---|
| 2000 | ~10,000 |
| 2006 | ~60,000 |
| 2012 | ~150,000 |
| 2018 | ~250,000 |
| 2024 | ~450,000 |

**Callout:**
44%
Are in the US

### Many trials compete for the same patients
![Icon representing three people](image_placeholder_for_people_icon)

### Studies are more complex and take longer
![Icon representing a person and a clock](image_placeholder_for_person_clock_icon)

....$2.6B
To develop a single drug

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 4: The solution

# RIGHT.
The solution
Leveraging AI to build a unique network of connected sites, sponsors & CROs

### RESEARCH SITES
- Smooth operations
- Improve site capabilities
- Bring more options to patients
- Increase revenue
- Free of Charge for Research

### SPONSORS & CROs
- Analyze data
- Generate documents
- Communicate with sites
- Onboard the “Ryght sites” for trials
- Complete studies faster

### ECOSYSTEM PARTNERS
- Build GenAI into their offerings and leverage Ryght network

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 5: The vision

# RIGHT.
The vision
AI to automate connected sites, sponsors & CROs

## Diagram Description:
A central AI neural network icon is connected to Sponsors, CROs, and Sites, overlaid on a world map, illustrating a global network automated by AI.

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 6: The Opportunity

# RIGHT.
The Opportunity

**Pie Chart: GLOBAL CLINICAL TRIAL MARKET SIZE, 2023**
(Center: $81B)

| Segment | (Implied Percentage/Size) |
|---|---|
| Pharmaceutical & Biopharmaceutical Companies | Largest segment |
| Medical Device Companies | Mid-size segment |
| Others | Smallest segment |

Growing at 11% CAGR

Labor accounts for
80%-95% of a clinical
trial's direct costs.

Ryght GenAI reduces
friction, improves
efficiency and speeds
time to market

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 7: Company

# RIGHT.
Company

© 2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 8: Team

# RIGHT.
Team
Former Deep Lens team working together to go much bigger

**Simon Arkell, CEO & Co-Founder**
Founder Deep Lens (exit), Predixion (exit), B. Econ., MBA, Olympian

**Alex Dickinson, Exec Chair & Co-Founder**
Founder Luxtera ($660M exit), Helixis ($105M exit) and Chromacode. SVP Illumina. BE, MBA, PhD (AI). PRA board member whose introduction led to Deep Lens exit.

**Dr. Chadi Nabhan, MD MBA, CMO**
Award winning Hematologist & Oncologist, Prior Chief of Oncology, Researcher, Author, Podcaster, prior CMO of significant industry players in GPO, healthtech, and a leader in precision medicine. Deep Lens advisor

**John Crupi, CTO & Co-Founder**
JackBe (exit), Predixion (exit), Software AG, Sun Microsystems (CTO Web Services). Real time streaming analytics expert. BS, MS. Early Deep Lens advisor

**Tyrone Richardson, CCO & Co-Founder**
VP Sales Deep Lens (exit), Caris, Inform Diagnostics. BS (bus), MBA.

**Dr. Deborah Fridman, PsyD, RN, SVP of Clinical Operations**
SVP, Clinops, Immunity Bio ($4B biotech); Exec Director of clinical research, Hoag Hospital - Deep Lens' first site.

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 9: The Ryght solution

# RIGHT.
The Ryght solution

> **World class AI software platform**
> Secure, industry trained, future proof. Completed 2023

> **Industry leading site & sponsor copilots**
> AI copilots to help sites, sponsors and CROs run smoothly, grow revenues, reduce cost and identify new opportunities. 2024 and beyond

> **Global Ryght Network**
> AI enabled sites, CROs, sponsors and partners utilizing AI as an underlying fabric to connect systems, and to connect to each other. Build out 2024, scale 2025

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 10: The Ryght Platform

# RIGHT.
The Ryght Platform
Launched Jan 2024.

- ![Life Science Domain Expertise icon](image_placeholder_for_gear_brain_icon)
  Life Science Domain
  Expertise
- ![Secure, Enterprise Scale icon](image_placeholder_for_padlock_icon)
  Secure, Enterprise Scale
- ![Connect Enterprise Data icon](image_placeholder_for_folder_ribbon_icon)
  Connect Enterprise
  Data

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 11: Platform: Secure public and client data & models

# RIGHT.
Platform: Secure public and client data & models

### Public industry resources
- PubMed
- ClinVar
- OHDSI
- NATIONAL CANCER INSTITUTE NIH GDC Data Portal
- ICD-10 www.cms.gov/ICD10
- MeSH

### Enterprise data connectors
- PDF (logo)
- X (logo)
- W (logo)
- A (logo)
- (Generic square C logo)
- (Snowflake logo)

### Commercial and open source models
- redis (logo)
- OpenAI (logo)
- Hyena DNA (logo)
- cpt (logo)
- aws (logo)
- Azure (logo)
- (Happy face icon)
- (Generic square CO logo)

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 12: Platform: Where we sit in the stack

# RIGHT.
Platform: Where we sit in the stack

### Application (copilot) Layer
| RIGHT. Copilots | Customer Copilots |
|---|---|
| SDK | Copilot Builder |

### Platform Layer
# RIGHT.
Auth2 | Analytics | Org Admin Portal

### Model Layer
| | | | |
|---|---|---|---|
| ![OpenAI logo](image_placeholder) | ![AI logo](image_placeholder) | ![Gemini logo](image_placeholder) | All Opensource |

### Infrastructure Layer
| | | | |
|---|---|---|---|
| ![aws logo](image_placeholder) | ![Azure logo](image_placeholder) | ![Google Cloud logo](image_placeholder) | ![ORACLE logo](image_placeholder) |

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 13: Platform: Scaling with self service tools

# RIGHT.
Platform: Scaling with self service tools

### No-Code Builder
(Screenshot of "Copilot Details" interface)
- **Copilot Details**
  - **General**
    - Breast Cancer Research Copilot
    - Our internal researchers to respond to PI requests quickly
  - **Features**
  - **AI Tags**
  - **Sharing**
- **Add suggestions**
  - Suggestion 1: Based on this collection what are the major causes of breast cancer
  - Suggestion 2: Describe the diagnostic process for stage 3 breast cancer
  - Suggestion 3: What is SOC therapy for TNB in Brazil?
  - Suggestion 4: Explain the relevance of BRCA mutations in LOH scoring
  - External URL: Enter URL
- (Save button)
- (Published toggle)

**Examples of No-Code Builder outputs:**
- Site Feasibility for CROs
- Breast Cancer Research Copilot
- Acute Pain Management
- Sargon Overview

### SDK
(Screenshot of Python code editor)
```python
In [1]:
from dotenv import find_dotenv
from ryght.utils import FlowTypes
from ryght.configs import Credentials
from ryght.clients.user import RyghtClient, DevClient
from ryght.models import ChunkedDocumentCollection, JsonDocument
from ryght.utils import initialize_logging, ModelOperation
from ryght.utils import QnARating
from result import Result, Ok, OkErr

In [2]:
import logging
logger = initialize_logging('../logs/playground.logs', log_level=logging.DEBUG)

In [3]:
# Create Ryght User Client
# Provide Credentials via dictionary
creds = {
    'username': 'userid',
    'password': 'Password',
    'client_id': 'client_id',
    'client_secret': 'fsdfsdf',
    'organization': 'Ryght Community'
}
# Load credentials from environment variable
```
(Screenshot of "nmible Patient Payments" application for "AB0001 in Essential Hypertension")

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 14: Copilots to support the entire drug development process

# RIGHT.
Copilots to support the entire drug development process
Current Roadmap

| Phase        | Sites                   | Sponsors & CROs                  |
|--------------|-------------------------|----------------------------------|
| **Pre-Trial**| Literature Review       | Study Discovery                  |
|              | Competitive Intel       | Proposal Writer                  |
|              | Study Design            | Protocol Writer                  |
|              | Protocol Drafting       | Chat with Regulatory             |
|              | Informed Consent Writer | Informed Consent Writer          |
|              | Consent Forms           | Chat With Protocol               |
| **Clinical Trial**| Study Feasibility    | Feasibility Request              |
|              | Site Selection          | Site selection                   |
|              | Patient Enrollment      | Real-time enrollment             |
|              | Doc and Reporting       | Audit and Data Quality           |
| **Post-Trial**| Manuscript Drafting    | Manuscript Drafting and Submission |
|              | Regulatory Docs         | Pharmacovigilance                |

**Ryght Trial AI (Data/AI Moat)** connects:
- Literature Review
- Chat With IB
- Chat With Protocol
- Feasibility Response
- Site Initiation
- Study Closure
- Problem Studies
- Feasibility Solution
- Real-time enrollment
- CUSTOM SITE COPILOTS

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 15: First copilots

# RIGHT.
First copilots

- **Informed Consent Builder**
    - Create an ICF in one hour, not 20
    - Adheres to multiple regulatory bodies such as the US, EMEA, Australia, & Japan
    - Helps for IITs and Grant submissions.

- **Regulatory Chat**
    - Search, summarize, and compare multiple regulatory sources and guidance documents.
    - Drill down to a specific paragraph to cite the source of information.
    - Aids sites in maintaining docs needed for regulatory audits and educates them

- **Proposal Builder**
    - Helps CROs generate proposals to sponsors and/or sites based on need, in under one hour
    - Leverages client's data and prior documents, and customizes output based on protocol/variables

- **Feasibility Accelerator**
    - Generates the feasibility questionnaire for CROs/sponsors, loads site target list, submits feasibility request to sites.
    - Sites use it to respond to any feasibility request from CROs/Sponsors rapidly
    - Track all feasibility requests in process. Reduces time to respond.
    - Leads to more studies matching site capabilities - incl registry

- **Protocol Chat**
    - This copilot intelligently summarizes 100s of protocols.
    - The Protocol Chat Copilot is specifically optimized to provide relevant responses to any kind of queries for any and all protocols.

- **Competitive Trial Intelligence**
    - Analyzes exc/inc criteria of studies in the desired space
    - Segments successful versus failing studies
    - Analyzes endpoints of studies
    - Proposes optimal trial design positioned for success
    - Accelerates enrollment for studies that are not enrolling timely

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 16: Site Network Go To Market

# RIGHT.
Site Network Go To Market

## Diagram Description:
The Ryght platform connects to:
- **SMOs/Networks** (Rev Share)
- **CRO**
- **Sponsor**

CRO and Sponsor connect to a **Feasibility App**.

The Feasibility App and "Direct IDNs AMCs" connect to various **Sites** organized by therapeutic area:
- **Oncology** (multiple sites)
- **Cardio** (multiple sites)
- **Metabolic** (multiple sites)
- **Autoimmune** (multiple sites)
- **Neuro** (multiple sites)
- **Other** (multiple sites)

© 2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 17: Commercial Go To Market

# RIGHT.
Commercial Go To Market

## Funnel Diagram:

### Channels:
- Channel
- Social
- SEO/SEM
- Email
- PR
- Advertising

### Top of Funnel Engagement:
- CRO
- Sponsor
- Healthtech

### Sales Stages:
- **Land:**
  - Preview
    - *Conversion campaigns to drive Preview users to Enterprise deal funnel*
- **Expand:**
  - Enterprise

### Sales Motion:
- Leads converting directly to sales team (without trying preview)
- Inside Sales/SDR
- Direct Sales Team

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 18: Traction Since January 2024 launch

# RIGHT.
Traction Since January 2024 launch
$460,000 ARR across 6 paid SaaS subscriptions

**Line Chart: Monthly Recurring Revenue (MRR)**

| Date      | MRR ($) |
|-----------|---------|
| 2/1/2024  | ~14,000 |
| 3/1/2024  | ~10,000 |
| 4/1/2024  | ~18,000 |
| 5/1/2024  | ~32,000 |
| (implied June 2024) | ~39,000 |

*Includes 3 deals confirmed and in legal

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 19: Competitive Landscape

## 2x2 Matrix: Enterprise capability vs. Biopharma expertise

**Y-axis: Enterprise capability**
- General-purpose (bottom)
- Enterprise (top)

**X-axis: Biopharma expertise**
- Individual (left)
- Biopharma-specific (right)

---

**Top-Left (Enterprise, General-purpose):**
- C3.ai
- glean
- H2O.ai
- PRYON

**Top-Right (Enterprise, Biopharma-specific):**
- Autonomize
- RIGHT.

**Bottom-Left (Individual, General-purpose):**
- Consumer Chatbots
- Gemini
- AI (generic AI logo)

**Bottom-Right (Individual, Biopharma-specific):**
- HUMA.AI
- pear
- Ferma
- scite_

---

## Slide 20: Company Timeline

# RIGHT.
Company Timeline

| Quarter | Event                     | Funding / Other              |
|---------|---------------------------|------------------------------|
| 1Q23    | Idea Hatched              |                              |
| 2Q23    | Company Incorporated      | $3M SAFE Note                |
|         | Coding Begins             |                              |
| 3Q23    | Signed hcl Commercial Agreement | Additional $1.25M added to SAFE Note |
|         |                           | *Virtue., AIX Ventures, PAGE ONE VENTURES, TOP HARVEST CAPITAL, iaso VENTURES* (Logos) |
| 4Q23    | Platform GA Announced     |                              |
| 1Q24    | 5 new SaaS Licenses Signed | SAFE #2                      |
| 2Q24    | Ryght Preview Launch      |                              |

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 21: Finance Projections

# RIGHT.
Finance
Projections

|                               | **2023 (Actual)** | **2024**       | **2025**       | **2026**       | **2027**       |
|:------------------------------|:------------------|:---------------|:---------------|:---------------|:---------------|
|                               | **$k**     | **%**      | **$k**  | **%**      | **$k**  | **%**      | **$k**  | **%**      | **$k**  | **%**      |
| **Customer Metrics (EOY)**    |                   |                |                |                |                |
| ARR ($000s) - SaaS            | -                 | 13             | $6,384  |                | $16,165 |                | $33,057 |                |
| ARR ($000s) - Network Access  | -                 | $1,615         | $500    |                | $9,500  |                | $24,500 |                |
| **Total ARR**                 | **-**             | **$1,615**     | **$6,884**     |                | **$25,665**    |                | **$57,557**    |                |
| YoY Growth                    |                   |                | 295%           |                | 153%           |                | 104%           |                |
| **Revenue - SaaS**            | -                 | 348            | 100%           | 3,280   | 96%            | 10,622  | 72%            | 23,672  | 56%            |
| **Revenue - Network Access**  | -                 | 0%             | 125     | 4%             | 4,188   | 28%            | 18,250  | 44%            |
| **Total Revenue**             | **-**             | **348**        | **100%**       | **3,405**   | **100%**       | **14,809**  | **100%**       | **41,922**  | **100%**       |
| Cost of revenue\*             | -                 | 214            | 61%            | 1,074   | 33%            | 2,517   | 24%            | 5,010   | 21%            |
| **Gross profit**              | **-**             | **134**        | **39%**        | **2,331**   | **68%**        | **12,292**  | **83%**        | **36,912**  | **88%**        |
| **Operating Expenses**        |                   |                |                |                |                |
| Product Development           | 738               | 1,765          | 508%           | 2,746   | 81%            | 4,433   | 30%            | 6,272   | 15%            |
| Sales                         | 508               | 456            | 131%           | 1,035   | 30%            | 2,687   | 18%            | 5,230   | 12%            |
| Marketing                     | -                 | 493            | 142%           | 700     | 21%            | 1,275   | 9%             | 2,064   | 5%             |
| General & Administrative      | 497               | 976            | 281%           | 1,594   | 47%            | 2,017   | 14%            | 2,643   | 6%             |
| **Total Operating Expense**   | **1,743**         | **3,690**      | **1062%**      | **6,075**   | **178%**       | **10,413**  | **70%**        | **16,209**  | **39%**        |
| **EBITDA**                    | **(1,743)**       | **(3,556)**    | **-1023%**     | **(3,743)** | **-110%**      | **1,879**   | **13%**        | **20,703**  | **49%**        |
| Headcount                     | 9                 | 25             |                | 49      |                | 62      |                | 79      |                |
| Revenue Per Employee ($000s)  | $                 | 14             |                | $67     |                | $171    |                | $300    |                |
| EBITDA Per Employee ($000s)   | $(194)$           | $(142)$        |                | $(76)$  |                | $30     |                | $262    |                |
| Ending Cash (000s)            | $3,100            | $1,063         |                | $6,455  |                | $5,678  |                | $22,908 |                |
| **Funding Plan**              |                   | 1,580 (Q2)     |                | 10,000 (Q1)    |                |                |                |                |                |

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 22: Current Customers

# RIGHT.
Current Customers

| Company    | Company Type       | Co-pilots\*                                       | Number of Users | EOY ARR    |
|:-----------|:-------------------|:--------------------------------------------------|:----------------|:-----------|
| McKesson   | RWE, Site, CRO     | EMR Extraction & Trial Docs                       | 14              | $150,000   |
| Hcl        | Lab Tech           | Disease Research & Misc. Test                     | 10              | $90,000    |
| Nmible     | Trial Tech         | Trial Participant Reimbursement                   | 4               | $145,000   |
| Surge      | Biotech            | Disease Research, Trial Docs                      | 2               | $25,000    |
| Bek Health | Site Tech          | Feasibility                                       | 2               | $25,000    |
| Avance     | CRO                | Feasibility                                       | 0               | $25,000    |
| Sargon     | Trial Site         | Chat with Protocol, Chat with IB, Feasibility (future) | 4               | NA         |
| SOCRU      | Trial Site         | Chat with Protocol, Chat with IB, Feasibility (future) | 8               | NA         |
| **Total**  |                    |                                                   | **42**          | **$460,000** |

\* all customers are able to leverage copilot Builder

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 23: Internal Simon Crib Notes

# RIGHT.
Internal Simon Crib Notes

| Company    | Company Type       | Co-pilots\*                                       | Number of Users | Reference  | EOY ARR    |
|:-----------|:-------------------|:--------------------------------------------------|:----------------|:-----------|:-----------|
| McKesson   | RWE, Site, CRO     | EMR Extraction & Trial Docs                       | 14              |            | $150,000   |
| Hcl        | Lab Tech           | Disease Research & Misc. Test                     | 10              | Bill, Charlie | $90,000    |
| Nmible     | Trial Tech         | Trial Participant Reimbursement                   | 4               | Jon        | $145,000   |
| Surge      | Biotech            | Disease Research, Trial Docs                      | 2               | Shane      | $25,000    |
| Bek Health | Site Tech          | Feasibility                                       | 2               |            | $25,000    |
| Avance     | CRO                | Feasibility                                       | 0               |            | $25,000    |
| Sargon     | Trial Site         | Chat with Protocol, Chat with IB, Feasibility (future) | 4               | Carrie     | NA         |
| SOCRU      | Trial Site         | Chat with Protocol, Chat with IB, Feasibility (future) | 8               |            | NA         |
| **Total**  |                    |                                                   | **42**          |            | **$460,000** |

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 24: Fundraising

# RIGHT.
Fundraising
SAFE Note $3M (Q2 2024); $10M+ Series A Q4 '24

- **Product:**
    - Grow enterprise functionality
    - Release self-service no code copilot builder and build 30+ copilots
    - Develop more enterprise connectors
    - Complete and distribute “feasibility accelerator"
- **Marketing & Commercialization:**
    - Position as the defacto GenAI platform provider and AI-enabled site network
    - Push co-pilot content (videos, webinars etc) to drive demand to sponsors and sites
    - Build direct sales force and BDMs across key partners
    - Prove repeatable sales model for sites and customers

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 25: Thank you!

Thank you!

Simon Arkell
CEO, Co-founder
simon@ryght.ai

Alex Dickinson
Exec Chair, Co-founder
alex@ryght.ai

# RIGHT.

© 2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.